Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

181. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. (Full text)

Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. Objective To examine clinical effectiveness and safety of apixaban 2.5 mg, dabigatran 110 mg, and rivaroxaban 15 mg compared with warfarin among patients with atrial fibrillation who had not previously taken an oral anticoagulant.Design Propensity weighted (inverse probability of treatment weighted) nationwide (...) cohort study.Setting Individual linked data from three nationwide registries in Denmark.Participants Patients with non-valvular atrial fibrillation filling a first prescription for an oral anticoagulant from August 2011 to February 2016. Patients who filled a prescription for a standard dose non-vitamin K antagonist oral anticoagulant (novel oral anticoagulants, NOACs) were excluded. To control for baseline differences in the population, a propensity score for receipt of either of the four treatment

2017 BMJ PubMed

182. Management of Isolated Calf DVTs with Anticoagulation

Management of Isolated Calf DVTs with Anticoagulation Emergency Medicine > Journal Club > Archive > August 2016 Toggle navigation August 2016 Management of Isolated Calf DVTs with Anticoagulation Vignette Mr. M is a 53-year-old patient with a history of high blood pressure and high cholesterol who flew back to St. Louis from Shanghai five days ago. Two days after getting back he noted pain and swelling in his left calf, which he thought was due to a muscle strain while getting off (...) of years that spoke about the controversy surrounding this dogma. You send Mr. P home and recommend repeat dopplers in 5-7 days, but later decide to search the literature in order to make your own evidence-based decision... PICO Question Population: Adult patients with isolated calf DVT distal to the popliteal veins Intervention: Therapeutic anticoagulation (heparin, low molecular weight heparin, factor Xa inhibitor, direct thrombin inhibitor, or vitamin K antagonist) Comparison: No anticoagulation

2017 Washington University Emergency Medicine Journal Club

183. Anticoagulants in non-valvular atrial fibrillation

Anticoagulants in non-valvular atrial fibrillation Anticoagulants in non-valvular atrial fibrillation Anticoagulants in non-valvular atrial fibrillation Van Brabandt H, San Miguel L, Fairon N, Vaes B, Henrard S, Boshnakova A, Cook R, Davies R, Karnad A, Lovell A, Dubois C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Van Brabandt H, San (...) Miguel L, Fairon N, Vaes B, Henrard S, Boshnakova A, Cook R, Davies R, Karnad A, Lovell A, Dubois C. Anticoagulants in non-valvular atrial fibrillation. Brussels: Belgian Health Care Knowledge Centre (KCE). KCE Reports. 2017 Authors' conclusions • International practice guidelines recommend prescribing anticoagulants to patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score ≥ 2 (for men) and score ≥ 3 (for women). For a CHA2DS2-VASc score = 0 they are best not prescribed. In patients

2017 Health Technology Assessment (HTA) Database.

184. Idarucizumab for Reversing Anticoagulation in Adults Treated with Dabigatran: A Review of the Clinical Effectiveness, Cost-effectiveness, and Guidelines

Idarucizumab for Reversing Anticoagulation in Adults Treated with Dabigatran: A Review of the Clinical Effectiveness, Cost-effectiveness, and Guidelines Idarucizumab for Reversing Anticoagulation in Adults Treated with Dabigatran: A Review of the Clinical Effectiveness, Cost-effectiveness, and Guidelines | CADTH.ca Find the information you need Idarucizumab for Reversing Anticoagulation in Adults Treated with Dabigatran: A Review of the Clinical Effectiveness, Cost-effectiveness, and Guidelines (...) Idarucizumab for Reversing Anticoagulation in Adults Treated with Dabigatran: A Review of the Clinical Effectiveness, Cost-effectiveness, and Guidelines Published on: January 31, 2017 Project Number: RD0035-000 Product Line: Research Type: Drug Report Type: Peer-reviewed summary with critical appraisal Result type: Report Question What is the comparative effectiveness and safety of idarucizumab versus standard supportive care for reversing the anticoagulation state in adults treated with dabigatran

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

185. Systematic review: Patients who self-monitor or self-manage can improve the quality of their oral anticoagulation therapy

Systematic review: Patients who self-monitor or self-manage can improve the quality of their oral anticoagulation therapy Patients who self-monitor or self-manage can improve the quality of their oral anticoagulation therapy | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Patients who self-monitor or self-manage can improve the quality of their oral anticoagulation therapy Article Text Community and primary care nursing Systematic

2017 Evidence-Based Nursing

186. Anticoagulants in non-valvular atrial fibrillation

Anticoagulants in non-valvular atrial fibrillation 2017 www.kce.fgov.be KCE REPORT 279 ANTICOAGULANTS IN NON-VALVULAR ATRIAL FIBRILLATION 2017 www.kce.fgov.be KCE REPORT 279 HEALTH TECHNOLOGY ASSESSMENT ANTICOAGULANTS IN NON-VALVULAR ATRIAL FIBRILLATION HANS VAN BRABANDT, LORENA SAN MIGUEL, NICOLAS FAIRON, BERT VAES, SEVERINE HENRARD, ANELIA BOSHNAKOVA, ROB COOK, ROB DAVIES, ADITI KARNAD, ALAN LOVELL, CECILE DUBOIS COLOPHON Title: Anticoagulants in non-valvular atrial fibrillation Authors: Hans (...) responsibility of the KCE. Publication date: 9 januari 2017 Domain: Health Technology Assessment (HTA) MeSH: atrial fibrillation; anticoagulants; secondary prevention; Belgium; cost-benefit analysis; Practice Patterns, Physicians'; Practice Guidelines as Topic NLM Classification: QV 193 Language: English Format: Adobe® PDF™ (A4) Legal depot: D/2016/10.273/101 ISSN: 2466-6459 Copyright: KCE reports are published under a “by/nc/nd” Creative Commons Licence http://kce.fgov.be/content/about-copyrights-for-kce

2017 Belgian Health Care Knowledge Centre

187. Myths and Realities: Is My Cirrhotic Patient Auto-anticoagulated?

Myths and Realities: Is My Cirrhotic Patient Auto-anticoagulated? Myths and Realities: Is My Cirrhotic Patient Auto-anticoagulated? – Clinical Correlations Search Myths and Realities: Is My Cirrhotic Patient Auto-anticoagulated? January 12, 2017 6 min read By B. Corbett Walsh, MD Peer Reviewed Case: A 65 year-old man with cirrhosis is admitted to the ICU for severe pneumonia. His hepatic dysfunction is chronically severe, as indicated by a MELD score of 31, and he has a stable thrombocytopenia (...) of 110,000 platelets/ml. Should this patient be on DVT prophylaxis? MYTH: Patients with severe hepatic dysfunction resulting in a significantly elevated INR are auto-anticoagulated and protected against venous thromboembolic events. The liver is responsible for a plethora of processes: metabolic (carbohydrate and lipid metabolism, regulating the levels of glucose in the blood), storage (glycogen, triglycerides, iron, vitamins, minerals, etc), catabolic (hormones, proteins, drugs, toxins, alcohol

2017 Clinical Correlations

188. Observational study: In patients with intracerebral haemorrhage and concomitant atrial fibrillation, optimal timing of reinitiating anticoagulants may be 7?8 weeks after ICH

Observational study: In patients with intracerebral haemorrhage and concomitant atrial fibrillation, optimal timing of reinitiating anticoagulants may be 7?8 weeks after ICH In patients with intracerebral haemorrhage and concomitant atrial fibrillation, optimal timing of reinitiating anticoagulants may be 7–8 weeks after ICH | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser (...) atrial fibrillation, optimal timing of reinitiating anticoagulants may be 7–8 weeks after ICH Article Text Therapeutics/Prevention Observational study In patients with intracerebral haemorrhage and concomitant atrial fibrillation, optimal timing of reinitiating anticoagulants may be 7–8 weeks after ICH Catharina JM Klijn , Floris HBM Schreuder Statistics from Altmetric.com Commentary on: Pennlert J, et al . Optimal timing of anticoagulant treatment after intracerebral haemorrhage in patients

2017 Evidence-Based Medicine (Requires free registration)

189. Cohort study: Resumption of anticoagulation after major bleeding decreases the risk of stroke in patients with atrial fibrillation

Cohort study: Resumption of anticoagulation after major bleeding decreases the risk of stroke in patients with atrial fibrillation Resumption of anticoagulation after major bleeding decreases the risk of stroke in patients with atrial fibrillation | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Resumption of anticoagulation after major bleeding decreases the risk of stroke in patients with atrial fibrillation Article Text

2017 Evidence-Based Medicine (Requires free registration)

191. Antiplatelet and anticoagulant drugs for ST-elevation myocardial infarction (STEMI)

Antiplatelet and anticoagulant drugs for ST-elevation myocardial infarction (STEMI)

2017 DynaMed Plus

192. Antiplatelet and anticoagulant drugs for elective percutaneous coronary intervention (PCI)

Antiplatelet and anticoagulant drugs for elective percutaneous coronary intervention (PCI)

2017 DynaMed Plus

199. Long-acting anticoagulant rodenticides (superwarfarins) toxicity - emergency management

Long-acting anticoagulant rodenticides (superwarfarins) toxicity - emergency management

2017 DynaMed Plus

200. Anticoagulation - oral

Anticoagulation - oral Anticoagulation - oral - NICE CKS Clinical Knowledge Summaries Share Anticoagulation - oral: Summary There are five oral anticoagulants licensed for use in the UK: warfarin, apixaban, dabigatran, edoxaban and rivaroxaban. Apixaban, dabigatran, edoxaban and rivaroxaban are newer anticoagulants which may be prescribed instead of warfarin for people with non-valvular atrial fibrillation (NVAF): Apixaban, dabigatran, edoxaban and rivaroxaban have been approved by the National (...) (INR) monitoring. However, regular follow up and monitoring is still required to: Assess compliance. Enquire about the presence of any adverse effect (e.g. bleeding). Assess for the presence of thromboembolic events (e.g. symptoms of stroke, or breathlessness which may suggest a pulmonary embolism). The most common adverse effect of anticoagulants is bleeding; however, while there is an antidote for warfarin, of the new anticoagulants, there is currently only an antidote for dabigatran. Management

2017 NICE Clinical Knowledge Summaries